Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects
with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale-
Revised (ALSFRS-R) score from baseline up to Week 48:
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.